CMX157: Phase I/IIa started

ContraVir began a dose-escalation, Thai Phase I/IIa trial of once-daily oral CMX157 in 50 healthy volunteers and 60 treatment-naive patients. The single-blind, placebo-controlled Phase I portion will ...